Science Explorer Interactive view Map
Company · Breda · Netherlands

UCB Pharma (Netherlands)

ucb.comROR OpenAlex
Research works
9
▼ 21% vs 2013–17
Citations
282
32.8 per fractional work
Top-10% rate
30.0%
record average 16.5%
Open access
66%
world 28%

Not ranked overall: UCB Pharma (Netherlands) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.72× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 4.12× its world share, 0 worksImmunology and Micro…Neuroscience: 5.44× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 21.16× its world share, 0 worksPharmacology, Toxico…Chemistry: 4.75× its world share, 0 worksChemistryMedicine: 2.79× its world share, 1 worksMedicineEconomics, Econometrics and Finance: 1.86× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 21.2×. Every wedge is a field page.

Which research topics does UCB Pharma (Netherlands) publish most on?

By volume in 2022–2025: Chemical synthesis and alkaloids, Traditional and Medicinal Uses of Annonaceae, Alkaloids: synthesis and pharmacology and Psoriasis: Treatment and Pathogenesis.

Chemical synthesis and a…0Chemical synthesis and alkaloids: 0 fractional worksTraditional and Medicina…0Traditional and Medicinal Uses of Annonaceae: 0 fractional worksAlkaloids: synthesis and…0Alkaloids: synthesis and pharmacology: 0 fractional worksPsoriasis: Treatment and…0Psoriasis: Treatment and Pathogenesis: 0 fractional worksCancer, Lipids, and Metabolism: 0 fractional worksNeuroscience and Neuropharmacology Research: 0 fractional worksHealth Systems, Economic…0Health Systems, Economic Evaluations, Quality of Life: 0 fractional worksFolate and B Vitamins Research: 0 fractional worksLipoproteins and Cardiovascular Health: 0 fractional worksSpondyloarthritis Studie…0Spondyloarthritis Studies and Treatments: 0 fractional works
Organic ChemistryBiochemistryPharmacologyImmunology5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Chemical synthesis and alkaloids Organic Chemistry 0 works
  2. 2 Traditional and Medicinal Uses of Annonaceae Biochemistry 0 works
  3. 3 Alkaloids: synthesis and pharmacology Pharmacology 0 works
  4. 4 Psoriasis: Treatment and Pathogenesis Immunology 0 works
  5. 5 Cancer, Lipids, and Metabolism Cancer Research 0 works
  6. 6 Neuroscience and Neuropharmacology Research Cellular and Molecular Neuroscience 0 works
  7. 7 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
  8. 8 Folate and B Vitamins Research Rheumatology 0 works
  9. 9 Lipoproteins and Cardiovascular Health Surgery 0 works
  10. 10 Spondyloarthritis Studies and Treatments Rheumatology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available66.3%not open33.7%

World: 28% of research is openly available.

with international co-authors66.1%domestic only33.9%

World: 19% is written across borders.

How has UCB Pharma (Netherlands)'s research output changed?

Output in 2018–2022 was 21% lower than in 2013–2017.

20002005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Breda

All research institutions in Breda

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.